Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Sponsor
Pak Emirates Military Hospital
Study ID
NCT07581418
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Methotrexate — DRUG
    Oral methotrexate administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.
  • Tofacitinib — DRUG
    Oral tofacitinib administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

Study Details

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

Key Dates

Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
88 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Methotrexate group
    Participants in this group will receive oral methotrexate according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.
  • Active Comparator: Tofacitinib Group
    Participants in this group will receive oral tofacitinib according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

Primary Outcome Measure

Change in Psoriasis Area and Severity Index (PASI) score [ Time Frame: 8 weeks ]

Central Contacts